Novartis acquires anti-clotting treatment from Portola

02/12/2009 |

Portola Pharmaceuticals agreed to sell rights to its anti-clotting drug elinogrel to Novartis AG. Elinogrel is undergoing midstage development and could be a major competitor to Plavix, a blockbuster drug by Bristol-Myers Squibb and Sanofi-Aventis. Portola initially will receive $75 million from Novartis and is entitled to as much as $500 million in milestone payments.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT